Alimera Sciences Receives New Coverage from Analysts at Northland Securities (ALIM)
Analysts at Northland Securities initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research report issued to clients and investors on Monday, Analyst Ratings Net reports. The firm set an “outperform” rating on the stock.
Shares of Alimera Sciences (NASDAQ:ALIM) traded down 2.11% on Monday, hitting $3.71. The stock had a trading volume of 236,705 shares. Alimera Sciences has a 52 week low of $1.26 and a 52 week high of $5.69. The stock has a 50-day moving average of $3.73 and a 200-day moving average of $3.95. The company’s market cap is $117.2 million.
Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Monday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.06. During the same quarter in the prior year, the company posted ($0.15) earnings per share. On average, analysts predict that Alimera Sciences will post $-1.18 earnings per share for the current fiscal year.
Alimera Sciences, Inc is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.